1,2,3-Selenadiazole thioacetanilides: Synthesis and anti-HIV activity evaluation

The development of new HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) offers the possibility of generating novel structures of increased potency. Based on the bioisosteric principle, novel series of 1,2,3-selenadiazole thioacetanilide derivatives were designed, and synthesized using an original synthetic route, structurally confirmed by spectral analysis, and evaluated for their anti-HIV activity in MT-4 cells. The results showed that only compound 7f possessed potent activity against HIV-1 replication (EC50 = 2.45 μM) similar to the prototype series of sulfanyltriazoles. None of the compounds were active against HIV-2 replication.

A series of novel 2-(4-(3,4-dichlorophenyl)-1,2,3-selenadiazol-5-ylthio)acetamides derivatives were synthesized using an original synthetic route, and tested against HIV in MT-4 cells. Compounds 7f (EC50 = 2.45 μM), 7h (EC50 = 5.42 μM), 7i (EC50 = 5.56 μM), 7k (EC50 = 6.65 μM), and 7l (EC50 = 5.59 μM), were found to be the most potent anti-HIV-1 agents of this series.Figure optionsDownload as PowerPoint slide